Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Short-course Romosozumab Followed by Denosumab Versus Zoledronic Acid: A Multicentre Randomized Active-controlled Trial in Postmenopausal Women at High Fracture Risk

NCT07772609 is registered in ClinicalTrials.gov with Sahlgrenska University Hospital as lead sponsor.

NCT NCT07772609
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07772609 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Short-course Romosozumab Followed by Denosumab Versus Zoledronic Acid: A Multicentre Randomized Active-controlled Trial in Postmenopausal Women at High Fracture Risk
Lead sponsor
Sahlgrenska University Hospital
Phase
Phase 4
Overall status
Not yet recruiting
Start date
January 11, 2027
Completion date
December 31, 2031
Enrollment
216 (estimated)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

osteoporosis in post-menopausal women